Advances in Targeted Therapy for Non-Small Cell Lung Cancer
Author Information
Author(s): Katzel Jed A, Fanucchi Michael P, Li Zujun
Primary Institution: Saint Vincent's Hospital, Manhattan and New York Medical College
Hypothesis
Can novel targeted therapies improve survival in patients with non-small cell lung cancer?
Conclusion
Recent targeted therapies have shown promise in improving survival rates for patients with advanced non-small cell lung cancer.
Supporting Evidence
- Targeted therapies like erlotinib and gefitinib have shown improved survival rates.
- Patients with specific genetic mutations respond better to targeted therapies.
- Combination therapies with chemotherapy and targeted agents have been explored.
Takeaway
Doctors are finding new medicines that can help people with lung cancer live longer and feel better.
Methodology
The study reviews various clinical trials and outcomes related to targeted therapies in non-small cell lung cancer.
Potential Biases
Potential bias in reporting outcomes from clinical trials may exist.
Limitations
The study primarily focuses on advanced stages of lung cancer and may not represent outcomes in earlier stages.
Participant Demographics
The majority of participants were previously treated patients with advanced non-small cell lung cancer.
Statistical Information
P-Value
<0.001
Confidence Interval
95% CI, 0.58–0.87
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website